OncoTEX Receives Notice of Allowance for Patent in Korea Regarding Ovarian Cancer-Fighting Drug OxaliTEX
Notice of allowance of OxaliTEX patent in Korea adds further global protection
OxaliTEX has already been granted patent protection in the
U.S., Australia, Singapore, Mexico and Israel
AUSTIN, Texas, March 30, 2022 (GLOBE NEWSWIRE) — OncoTEX Inc., an oncology company developing cancer pharmaceuticals that are tumor localizing, exhibit low side effects, target both drug-sensitive and drug-resistant solid tumors, and are MRI-detectable, today announced its novel cancer-fighting drug candidate, OxaliTEX, has received a notice of allowance for patent in Korea.
This notice will further broaden OxaliTEX’s global protection and strengthen its intellectual property portfolio. The OxaliTEX Patent Cooperation Treaty (PCT) application was first published in 2015 and has since been granted patent protection in the U.S., Australia, Singapore, Mexico, and Israel.
OncoTEX is developing TEX Core, a world-first oncology drug platform designed to create innovative therapies capable of overcoming multiple limitations often associated with current cancer therapeutics, including the predominant platinum-based resistance.
OxaliTEX is the first clinical candidate developed from the TEX Core platform for the treatment of platinum-resistant ovarian cancer. TEX Core is designed to target tumor cells by overcoming challenges associated with the current platinum-based standards-of-care (SOC).
More than 300,000 women globally are diagnosed with ovarian cancer each year, making ovarian cancer one of the leading causes of cancer-related death in women. This is because ovarian cancer is rarely symptomatic in its early stages and often untreatable by the time of detection.
OxaliTEX overcomes platinum resistance and is tumor localizing, well-tolerated, and MRI-detectable to allow clinicians and patients to easily monitor tumor regression. The OncoTEX pipeline consists of several drug candidates at different stages of development for the treatment of multiple cancer indications.
Dr. Jonathan Arambula, CEO of OncoTEX, said, “We are excited to receive this notice of allowance in Korea, broadening even further our global intellectual proprietary portfolio and opening the door for more people to receive OxaliTEX when it reaches the clinic. Greater global protection justifies our continued development through rigorous testing, bringing us one step closer to delivering our drug to market and in the hands of clinicians.”
About OncoTEX Inc.
OncoTEX Inc. is an oncology company developing the next class of cancer therapeutics. OncoTEX owns TEX Core, a novel oncology drug platform that enables the development of pharmaceuticals that are tumor localizing, exhibit low side effects, target both drug-sensitive and drug-resistant solid tumors, and are MRI-detectable. For more information visit oncotexinc.com
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, OncoTEX Inc.’s ability to develop and commercialize its product candidates originated from the TEX Core platform, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although OncoTEX Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. OncoTEX Inc. has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in the Company’s public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Dr. Jonathan Arambula, Chief Executive Officer
Info@OncoTEXInc.com
Investor Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
Tel: 1-212-896-1254
Email: OncoTEX@KCSA.com
